Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials

BMC Psychiatry

Alex Barker¹  Asres Berhan² 

[1] Veteran Affairs Medical Center, Iron Mountain, Michigan, USA;Hawassa University College of Medicine and Health Sciences, Hawassa, Ethiopia

关键词: Depression symptoms;    Serotonin;    Meta-analysis;    Major depressive disorder;    Vortioxetine;   

Others  :  1123317
DOI  :  10.1186/s12888-014-0276-x

 received in 2014-04-02, accepted in 2014-09-23,  发布年份 2014

【 摘 要 】

Background

Vortioxetine is a novel multimodal compound that has recently been approved by the FDA for the treatment of major depressive disorder (MDD). It is a selective serotonin (5-HT) 3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, 5-HT1A receptor agonist and inhibitor of serotonin transporters. The objective of this meta-analysis was to evaluate the efficacy and safety of vortioxetine in adults with MDD.

Methods

A literature search was conducted in the databases of PubMed, EMBASE, Cochrane library and HINARI. The meta-analysis was conducted by including randomized controlled trials that assessed the efficacy and safety of vortioxetine in adult patients with MDD. Using the random effects model, which assumes individual studies are estimating different treatment effects, the efficacy and safety of vortioxetine was determined by weighted mean differences (WMDs) and odds ratios (ORs). The findings were considered as statistically significant when the 95% CI of WMDs and ORs did not include 0 and 1, respectively. Heterogeneity testing, meta-regression and sensitivity analysis were also performed.

Results

During the initial literature search about 151 publications were identified. Based on the predetermined inclusion criteria, 7 randomized controlled trials were included. The pooled analysis demonstrated a statistically significant reduction in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score from baseline among patients who were on vortioxetine (WMD = −3.92; 95% CI, −5.258 to −2.581). Furthermore, a statistically significant number of patients with MDD who were on vortioxetine have achieved a greater than or equal to 50% reduction in depression symptoms from baseline. However, a significant number of patients who were on vortioxetine therapy reported more adverse events than patients who were on placebo (overall OR = 1.21; 95% CI, 1.06 to 1.38).

Conclusions

Therapy with vortioxetine was significantly associated with reduction in depression symptoms from baseline compared to placebo. Nevertheless, a significant number of patients who were on vortioxetine therapy have reported more adverse events.

【 授权许可】

   
2014 Berhan and Barker; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Pehrson AL, Sanchez C: Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014, 19(2):121-133.
• [2]Serretti A, Chiesa A: Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009, 29:259-266.
• [3]Ranjbar S, Pai NB, Deng C: The Association of Antidepressant Medication and Body Weight Gain. OJHAS 2013, 12(1):1-9.
• [4]Wu C, Gau SS, Lai M: Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case–control study in Taiwan [CME]. J Clin Psychiatry 2014, 75:31-38.
• [5]Halperin D, Reber G: Influence of antidepressants on hemostasis. Dialogues Clin Neurosci 2007, 9(1):47-59.
• [6]Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A, Stensbøl T: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011, 54(9):3206-3221.
• [7]Mork A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sanchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbol TB: Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder. J PHarmacol Exp Ther 2012, 340:666-675.
• [8]Areberg J, Søgaard B, Højer A: The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol 2012, 111:198-205.
• [9]Chen G, Lee R, Højer A, Buchbjerg JK, Serenko M, Zhao Z: Pharmacokinetic drug interactions involving Vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013, 33:727-736.
• [10]Alvarez E, Perez V, Dragheim M, Loft H, Artigas F: A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychoph 2012, 15:589-600.
• [11]Katona C, Hensen T, Olsen , Christina , Kurre , Olsen A, Christina A, Kurre A: A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int J Neuropsychoph 2012, 27:215-223.
• [12]Boulenger J, Loft H, Olsen CK: Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014, 29(3):138-149.
• [13]Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME: A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerablity of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012, 73:953-959.
• [14]Baldwin DS, Loft H, Dragheim M: A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharm 2012, 27:215-223.
• [15]Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME: A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychoph 2013, 16:313-321.
• [16]Mahableshwarkar AR, Jacobsen PL, Chen Y: A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013, 29:217-226.
• [17]Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH: Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw 2012, 49:5.
• [18]Alam MY, Jacobsen PL, Chen Y, Serenko M, Mahableshwarkar AR: Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int J Neuropsychoph 2014, 29:36-44.
• [19]Baldwin DS, Thomas H, Ioana F: Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin 2012, 28(10):1717-1724.
• [20]Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter Ioline D, Salvadore G, Zarate J, Carlos A: The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals 2010, 3:19-41.
• [21]Fanelli D: How many scientists fabricate and falsify research? a systematic review and meta-analysis of survey data. PLoS ONE 2009, 4(5):4:e5738.
• [22]Citrome L: Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014, 68:60-82.
• [23]Theunissen EL, Street D, Højer A, Vermeeren A, Van Oers A, Ramaekers JG: A randomized trial on the acute and steady-state effects of a new antidepressant, Vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013, 93:493-501.
• [24]Walker E, Hernandez AV, Kattan MW: Meta-analysis: its strengths and limitations. Clev Clin J Med 2008, 75:431-439.